Alpha Mannosidosis Market: By Treatment Type (Bone Marrow Transplant, and Enzyme Replacement Therapy), By Indication, (Type I, Type II, and Type III), By End User (Hospitals, and Specialty Clinics), and Geography  

Alpha Mannosidosis Market size was valued at USD 10.2 billion in 2023, growing at a significant CAGR of 18.8% from 2024-2030. The market is anticipated to expand during the forecast period due to rising research expenditures. Only one firm currently offers treatments for the rare hereditary illness alpha mannosidosis. However, several businesses are developing items that will drive up demand in the market throughout the projection period. For example, the EU clinical trials database includes 39,219 clinical trials with an EudraCT protocol in 2020, 6,426 of which involve participants under 18. Therefore, the alpha mannosidosis market is expanding due to rising research expenditures. The alpha mannosidosis market is starting to notice treatment innovations such as pharmaceutical therapy. For instance, the European Medicines Agency Committee for Medicinal Products for Human Use has approved Velmanase Alfa's marketing authorization under the trade name Lamzede, according to Chiesi Group, a global healthcare firm focusing on research. To replace or supplement natural alpha-mannosidase, which aids in the breakdown of mannose-rich oligosaccharides and inhibits their build-up in various bodily tissues, Lamzede is an enzyme replacement therapy. Based on market trends, strategies for alpha mannosidosis include expanding enzyme therapy, implementing hematopoietic stem cell transplantation, and implementing cisterna magna infusion.